Synergistic Pharmaceutical Compositions with Integrated Technologies

Publication ID: 24-11857625_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Pharmaceutical Compositions with Integrated Technologies,” Published Technical Disclosure No. 24-11857625_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857625_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,625.

Summary of the Inventive Concept

This inventive concept integrates the original pharmaceutical composition with advanced technologies, such as AI, IoT, blockchain, and novel materials, to create a more powerful and personalized system for pharmaceutical formulation, monitoring, and prediction.

Background and Problem Solved

The original patent relates to pharmaceutical compositions comprising an antibody, glycine, acetate buffer, and polysorbate 80. However, it has limitations in terms of stability, formulation, and personalization. The new inventive concept addresses these limitations by incorporating advanced technologies to enhance stability, optimize formulation, and provide personalized medicine.

Detailed Description of the Inventive Concept

The new inventive concept consists of synergistic combinations of the original pharmaceutical composition with advanced technologies. For instance, the system for monitoring and predicting pharmaceutical composition stability uses a blockchain-based database and an AI-powered algorithm to analyze stability data and predict potential instability. The method for optimizing pharmaceutical composition formulation employs an IoT-enabled sensor to monitor pH levels and adjust them in real-time to ensure stability. The pharmaceutical composition comprising a novel material with enhanced stability properties and a polysorbate 80 and acetate buffer system offers improved stability. The system for personalized medicine uses AI-powered algorithms to analyze patient-specific data and recommend personalized composition formulations. The method for predicting pharmaceutical composition stability using machine learning trains a model on a dataset of stability data to predict stability of new compositions.

Novelty and Inventive Step

The new claims introduce novel and non-obvious combinations of advanced technologies with the original pharmaceutical composition, providing a synergistic effect that enhances stability, optimizes formulation, and enables personalized medicine. The inventive step lies in the integration of these technologies to create a more powerful and effective system.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of other advanced technologies, such as quantum computing or nanotechnology, to further enhance the system's capabilities. Variations of the system could be designed for specific pharmaceutical applications, such as vaccine development or gene therapy.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the pharmaceutical industry, particularly in the areas of personalized medicine, pharmaceutical formulation, and stability monitoring. The target market includes pharmaceutical companies, research institutions, and healthcare providers seeking to improve the development and delivery of pharmaceutical products.

CPC Classifications

SectionClassGroup
A A61 A61K39/39591
A A61 A61K47/12
A A61 A61K47/183
A A61 A61K47/26
C C07 C07K16/244
C C07 C07K2317/76

Original Patent Information

Patent NumberUS 11,857,625
TitlePharmaceutical compositions
Assignee(s)UCB BIOPHARMA SRL